Gitnux/Report 2026

AI Virtual Cell Industry Statistics

The $1.8 billion 2026 public–private initiative, explore the figures behind AI virtual cell growth, company programs, and 2026 trends.
3Statistics
19Sources
1Sections
11mRead
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 44 days

01 Industry overview

The AI virtual cell industry at a glance

The AI virtual cell industry remains an emerging research market, backed by a $1.8 billion 2026 public–private initiative combining funding, data, computing and measurement technology.

$1.8B[4]
2026 initiative value
350M+[5]
Cells sequenced, 2026
€22M[3]
Rivercell seed round, 2026
$100K[6]
Virtual Cell Challenge prize
Forecast & CAGR
No direct market forecast for AI virtual cells was identified. The closest available proxy cited in 2026 coverage is the broader AI drug-discovery market, valued at $1.71 billion in 2024 and forecast to reach $8.52 billion by 2030, implying a 30.6% CAGR; this should not be interpreted as the size of the virtual-cell segment alone.[3]
Market share & regions
The United States currently anchors the field through major public, nonprofit and commercial programs, while Europe is developing dedicated startups: Paris-based Rivercell raised a €22 million seed round in October 2026. No reliable regional market-share percentages were identified.[4][3]
Segmentation
The industry is dividing into foundational data and atlas infrastructure, virtual-cell model development, benchmarking and drug-discovery applications. Illumina’s Billion Cell Atlas had sequenced more than 350 million cells by July 2026, while Rivercell is targeting oncology, immunology, rare disease and cardiometabolic conditions.[5][3]
Key players & concentration
The sector is concentrated around a small group of technology, pharmaceutical and nonprofit participants. Illumina’s alliance included AstraZeneca, Eli Lilly, Merck, Formation Bio and two additional AI-driven drug-discovery partners, while the broader universal-cell effort involves Google DeepMind, Isomorphic Labs, Meta, Biohub, DOE and NIH.[5][4]
Trends, drivers & challenges
Growth is being driven by large-scale perturbation datasets, automated laboratories and demand for virtual experiments that can reduce costly physical testing. The main technical constraints are limited high-quality causal data, weak transfer across laboratories and platforms, data leakage, coverage bias, and incomplete handling of dose, time and combination effects.[4][7]
Consumer behavior & competition
The primary buyers and users are pharmaceutical companies, biotechnology firms and research institutions rather than consumers. Competition is centered on proprietary experimental data, model generalization and benchmark performance: Arc’s challenge evaluates prediction of gene-perturbation responses, and Illumina’s alliance gives commercial partners access to large-scale cell data for drug development.[6][5]
Regulation
No virtual-cell-specific regulatory market statistics or dedicated approval framework were identified. Current development is primarily research-oriented, with field-building efforts focused on standardized benchmarks, reproducibility and transparent evaluation rather than regulatory authorization.[6][7]
Latest news
In October 2026, Biohub, Google, federal agencies and other partners announced a $1.8 billion effort involving funding, data, computing and measurement technology to create a universal virtual cell. In the same month, Paris-based Rivercell announced a €22 million seed round to build an automated wet lab and AI virtual-cell program.[4][3]

02 Ranking

Top 10 Companies in the AI Virtual Cell Industry

The leading companies in the AI virtual cell industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

GenBio AI stands out for multiscale whole-cell simulation because its AIDO Cell is a multiscale simulator for whole-cell biology, while Bioptimus is the pick for counterfactual cell and tissue simulations since it is building a multiscale biology model for those use cases.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in multiscale virtual-cell simulation

    GenBio AI

    US

    Ranked #1 · 9.3 · Multiscale virtual-cell simulation

    Why we picked it: Its AIDO Cell focuses on multiscale simulation for whole-cell biology.

  2. Leader in causal cellular modeling

    insitro

    US

    Ranked #3 · 9.1 · Causal cellular modeling

    Why we picked it: Its Virtual Human models use cellular and clinical data to support causal cellular modeling.

  3. Leader in perturbation modeling

    Tahoe

    US

    Ranked #4 · 8.7 · Perturbation modeling

    Why we picked it: It generates perturbative single-cell data and models how cells respond to unseen interventions.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the AI virtual cell industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

GenBio AI

Multiscale virtual-cell simulation · US

9.3
2

Bioptimus

Multiscale virtual-cell simulation · FR

9.2
3

insitro

Causal cellular modeling · US

9.1
4

Tahoe

Perturbation modeling · US

8.7
5

Xaira Therapeutics

Genetic perturbation outcome prediction · US

8.7
6

Recursion

AI virtual-cell and drug-discovery platform · US

8.5
7

Noetik

Cancer virtual-cell models · US

8.4
8

Cellular Intelligence

Virtual cell-signaling models · US

8.3
9

Cellarity

Cell-state modeling and therapeutics · US

8.0
10

InVirtuoLabs

AI virtual cells for drug discovery

7.3

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 19). Top 10 companies in the AI virtual cell industry. In AI Virtual Cell Industry Statistics. Gitnux. https://gitnux.org/ai-virtual-cell-industry-statistics/#top-companies

04 Statistics

Finance

Finance coverage in 2026 centers on public–private scale and startup funding. It cites more than $3 billion invested globally by 2026 and a €22 million Rivercell seed round announced on 7 October 2026.

Funding and investment in the AI virtual cell industry

  • More than $3 billion had been invested globally in AI virtual-cell companies by 2026, according to Dealroom’s sector note; the figure covers cumulative field funding, not software-only providers.[1]
  • $5 million was raised by ChemT Biotechnology in 2026 for its CelMo AI-powered virtual-cell platform for biomanufacturing.[2]
  • €22 million was raised in a seed round announced on 7 October 2026 by Rivercell to develop AI virtual-cell models and supporting data-generation infrastructure.[3]

Key questions about the AI virtual cell industry

How big is the AI virtual cell market in 2026?
More than $3 billion had been invested globally in AI virtual-cell companies by 2026, based on Dealroom’s sector note. This covers cumulative field funding, not software-only providers.
What growth or expansion figures are available for this industry?
No direct market forecast for AI virtual cells was identified. A 2026 proxy cited coverage values the broader AI drug-discovery market at $1.71 billion in 2024 and forecast to reach $8.52 billion by 2030, implying a 30.6% CAGR.
Which companies lead the AI virtual cell industry?
GenBio AI stands out for multiscale whole-cell simulation because its AIDO Cell is a multiscale simulator for whole-cell biology, while Bioptimus is the pick for counterfactual cell and tissue simulations since it is building a multiscale biology model for those use cases.
What technology shifts are showing up in 2026?
Growth drivers in 2026 include large-scale perturbation datasets, automated laboratories, and demand for virtual experiments. Technical constraints include limited high-quality causal data and weak transfer across laboratories and platforms.
How is the field structured by participants in 2026?
The sector is concentrated around a small group of technology, pharmaceutical, and nonprofit participants. The U.S. anchors the field through major public, nonprofit and commercial programs, while Europe is developing dedicated startups such as Paris-based Rivercell.
What is the latest scale of cell sequencing relevant to virtual-cell work?
Illumina’s Billion Cell Atlas had sequenced more than 350 million cells by July 2026. The 2026 industry-wide figure also lists 350M+ cells sequenced.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 19). AI Virtual Cell Industry Statistics. Gitnux. https://gitnux.org/ai-virtual-cell-industry-statistics
MLA
Samuel Norberg. "AI Virtual Cell Industry Statistics." Gitnux, 19 Nov 2026, https://gitnux.org/ai-virtual-cell-industry-statistics.
Chicago
Samuel Norberg. 2026. "AI Virtual Cell Industry Statistics." Gitnux. https://gitnux.org/ai-virtual-cell-industry-statistics.